ST-segment elevation myocardial infarction (STEMI) patients have better odds of survival if emergency medical services (EMS) personnel alert the hospital where the patient will be arriving ahead of time, according to a study published Sept. 17 in JACC: Cardiovascular Interventions.

WAYNE, N.J., May 25, 2018 — Getinge, a leading global provider of innovative medical technology, today announced results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP Implantation (SEMPER FI) pilot study.

Assessment of coronary physiology to guide revascularization decisions has been linked to lower adverse event rates than using angiography alone, but the adoption of techniques such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) continues to lag behind guideline recommendations.

Two late-breaking clinical trials presented May 23 at EuroPCR in London demonstrated the ability of renal denervation to significantly lower patients’ blood pressures, regardless of whether they were taking antihypertensive medications.

The FlowTriever System has become the first thrombectomy device designed to treat pulmonary embolism (PE) to be cleared by the FDA, Inari Medical announced in a May 21 press release.

At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.

A new device allows clinicians to remove blood clots from the pulmonary arteries and improve right ventricular function without the use of thrombolytics, according to a late-breaking clinical study presented April 26 at SCAI 2018 in San Diego.